Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World February 8, 2013 Andrew Turley	Biogen buys Tysabri from Elan for $3.25bn US biotech Biogen Idec is to pay $3.25 billion to Irish drugmaker Elan for full rights to Tysabri (natalizumab) injections for the treatment of multiple sclerosis.
The Motley Fool August 1, 2008 Brian Lawler	Elan Becomes a Bad News Buy Shares of Elan are now undervalued, thanks to a big price drop following bad new about their multiple sclerosis drug.
The Motley Fool June 29, 2009 Brian Orelli	Another Day, Another Rumored Suitor The rumors surrounding Elan's strategic review and its suitors just keep getting weirder.
The Motley Fool March 15, 2007 Anders Bylund	Dueling Fools: Elan Bull Granted, Elan isn't a stock for impatient investors, but those with patience will be rewarded in spades.
The Motley Fool July 30, 2007 Brian Lawler	The Good and Bad of Elan Investors, any bet on Elan is primarily a bet on the outcomes of Tysabri and AAB-001.
The Motley Fool April 25, 2007 Brian Lawler	Where Is Elan Going? Drugmaker Elan announces first-quarter financial results. Investors, take note.
The Motley Fool September 15, 2009 Brian Orelli	What's $115 Million Between Friends? Elan has to fix the mess it had gotten itself into with its multiple sclerosis drug Tysabri.
The Motley Fool February 10, 2009 Brian Orelli	Elan Needs a Face-Lift Elan is in need of a serious makeover. The company has been beaten down severely, but there's still plenty of beauty in this pharma.
The Motley Fool September 4, 2009 Brian Orelli	The Billion-Dollar Lovers' Quarrel Continues Elan had better bring candy and flowers to patch this up.
The Motley Fool February 22, 2007 Brian Lawler	Too Much Aplomb From Elan Elan releases its 2006 financial results, and its future is not as rosy as seems. Investors, take note.
Chemistry World February 27, 2013 Andrew Turley	Talk of a $6.6bn deal for Elan Irish drug maker Elan has been surprised by a potential $6.6 billion offer being mooted by investment firm Royalty Pharma.
The Motley Fool February 11, 2010 Brian Orelli	Blockbuster in Hand, It's Time to Show a Profit Elan predicts an operating profit for the first time in nine years.
The Motley Fool April 21, 2011 Brian Orelli	Tysabri Means Everything to Biogen and Elan ... for Now It's rare to find a drug that affects two companies as much as Tysabri does Biogen Idec and Elan.
The Motley Fool March 15, 2007 Brian Lawler	Dueling Fools: Elan Bear How do you bring an Elan bear out of hibernation? Combine a crushing debt load, a huge cloud of uncertainty over its lead developmental drug program, and the launch of a new product that won't bring in enough revenue to sustain the current valuation, et voila! A bear is born.
The Motley Fool October 31, 2006 Brian Lawler	A Foolish Trick: Elan Debt is coming due, and there's too much reliance on a single drug. Investors, beware.
The Motley Fool July 6, 2007 Brian Lawler	Elan Goes to the Isles The drugmaker wins an important battle in the U.K., but shares are still priced for more than perfection.
The Motley Fool August 4, 2010 Mac Greer	One Biotech Stock Ready to Rebound? One of our analysts gives you his thoughts on Elan.
The Motley Fool December 19, 2011 Brian Orelli	Elan Turns It Around in 2011 Let's hope next year is as productive.
The Motley Fool August 7, 2009 Brian Orelli	A Billion-Dollar Lovers' Quarrel It looks like the triangle between partners Elan and Biogen Idec and third-wheel Johnson & Johnson over the multiple sclerosis drug Tysabri is going to get settled in court.
The Motley Fool June 18, 2007 Billy Fisher	Elan Elevates Its Game New drug prospects push the Dublin-based biotech's shares to a new 52-week high.
The Motley Fool October 28, 2011 Brian Orelli	Focus on Profits, Biotech Investors Elan is in the black and looking as healthy as ever.
The Motley Fool January 21, 2011 Brian Orelli	Trouble in Tysabri Land? Patient additions for a drug from Biogen Idec and Elan are slowing down.
The Motley Fool February 9, 2011 Brian Orelli	Once a Decade Isn't Enough, Elan Elan posts its first operating profit in 10 years.
The Motley Fool March 8, 2005 Charly Travers	After the Crash, Is Biogen IDEC a Buy? Biogen stock plunge may be an overreaction to pulling multiple sclerosis drug Tysabri off the market.
The Motley Fool July 23, 2008 Brian Lawler	No Picking at Biogen At a time in which all of its top drugs experienced at least double-digit percentage sales growth, there aren't many issues to poke at with Biogen Idec's just-released second-quarter financial results.
The Motley Fool February 28, 2008 Brian Lawler	A Tysabri Heart Attack Biogen and Elan announce new warnings for multiple sclerosis drug Tysabri.
Chemistry World July 31, 2013 Daniel Johnson	Perrigo bags Elan and its bargain Irish tax rates US drugmaker Perrigo has agreed to buy Irish pharma company Elan in a deal worth $8.6 billion. This hands Perrigo a base in low-tax Ireland and annual savings of up to $150 million in tax and operating costs.
The Motley Fool April 23, 2009 Brian Orelli	Elan's Strategic Uncertainty Elan has nothing new to report yet on the strategic review that Citigroup is preparing for them.
The Motley Fool July 21, 2010 Brian Orelli	Biogen Looks Good Now, but What About Tomorrow? Biogen Idec saw revenue increase 11% and adjusted earnings per share jump almost 75%, which is all well and good, but the longer-term prospects for the company aren't nearly as impressive.
The Motley Fool October 22, 2009 Brian Orelli	Elan's Headed in the Right Direction Revenue up, costs down. It's a good direction for Elan to take, even if the company's final earnings number was slightly inflated.
The Motley Fool January 2, 2012 Anders Bylund	What Will Elan Do for an Encore? 2011 was a great year for the Irish biotech. Here's how that momentum carries through into 2012.
The Motley Fool October 5, 2006 Brian Lawler	Elan Extends Tysabri's Reach The MS-fighting drug gains approval in Canada. Next month, when Biogen and Elan report third-quarter results, investors will get a preliminary indication of how these sales of Tysabri are ramping up.
The Motley Fool July 24, 2007 Brian Lawler	Biogen's Steady Growth Biogen reports another good quarter of growth, both top- and bottom-line.
The Motley Fool December 15, 2009 Brian Orelli	Forget the Higher Doses Elan has to drop the highest dose of an Alzheimer's drug. Again.
The Motley Fool January 16, 2008 Brian Lawler	More Tysabri on the Way Biogen and Elan receive an additional approval for Tysabri. Investors, take note.
The Motley Fool July 17, 2009 Brian Orelli	Tysabri Is Back! News about Biogen Idec and Elan's multiple sclerosis drug revenues, as well as those of Pfizer and Teva.
The Motley Fool March 31, 2005 Stephen D. Simpson	Strike Three for Tysabri A third confirmed case of PML all but eliminates Tysabri's potential as a blockbuster drug. For Elan and Biogen investors, the news continues to sting.
The Motley Fool December 28, 2010 Brian Orelli	No Guts, No Glory For better or worse, Elan gains full control of Alzheimer's drug ELND005.
The Motley Fool October 24, 2008 Brian Orelli	Elan's Approaching the Black Elan doesn't have positive cash flow yet, but it's getting closer, with revenue and expenses headed in the right direction.
The Motley Fool June 1, 2009 Brian Orelli	Going Up for All the Wrong Reasons Bristol-Myers has been identified as Elan's mystery bidder. So what?
The Motley Fool April 5, 2005 Charly Travers	Has Elan Been KO'd? Tysabri is derailed but not necessarily off-track forever. The FDA needs to consider whether the real benefits to these patients outweigh the risk. But that's a highly uncertain outcome and a heck of decision on which to bet some investment dollars.
The Motley Fool October 24, 2007 Brian Lawler	Biogen's Brisk Business Following a rumor-filled and busy couple of weeks, Biogen releases its third-quarter financial results.
The Motley Fool October 29, 2004 Brian Gorman	Elan Bides Its Time Is the Irish pharmaceutical stronger from its near-death experience?
The Motley Fool December 6, 2005 Stephen D. Simpson	Tysabri Tries Again Will the FDA finally approve Elan's multiple sclerosis drug? Investors' fingers are crossed.
The Motley Fool February 27, 2009 Brian Orelli	Elan's Crash Diet Looks Good Elan needed a makeover, and the new, thinner company is looking better already.
The Motley Fool May 26, 2011 Brian Orelli	Intriguing, Potentially Lucrative, But Still Not Worth the Jump in Shares Elan sets up a drug development deal with Proteostasis.
The Motley Fool February 22, 2011 Brian Orelli	Biogen and Elan's Growing Problem More cases of potentially lethal PML.
The Motley Fool September 30, 2009 Brian Orelli	More Questions Than Answers From Elan Things that make you go hmmm.
The Motley Fool January 26, 2006 Bill Mann	Lehman Shows Little Elan At $17, maybe the stock was a little ahead of itself. But a $5 target? Last week, a Lehman Brothers analyst triggered a bit of a selling panic when he said that Elan Pharmaceuticals was overvalued -- by about 70%.
The Motley Fool April 25, 2008 Brian Lawler	Biogen's Big Step Forward Pharmaceutical company Biogen IDEC boasts better results and a rosier outlook.